These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. Brussee JM; Yu H; Krekels EHJ; de Roos B; Brill MJE; van den Anker JN; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):374-383. PubMed ID: 29745466 [TBL] [Abstract][Full Text] [Related]
7. Proof of Concept: First Pediatric [ van Groen BD; van Duijn E; de Vries A; Mooij MG; Tibboel D; Vaes WHJ; de Wildt SN Clin Pharmacol Ther; 2020 Nov; 108(5):1003-1009. PubMed ID: 32386327 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo glucuronidation of midazolam in humans. Hyland R; Osborne T; Payne A; Kempshall S; Logan YR; Ezzeddine K; Jones B Br J Clin Pharmacol; 2009 Apr; 67(4):445-54. PubMed ID: 19371318 [TBL] [Abstract][Full Text] [Related]
9. The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers. Miura M; Uchida S; Tanaka S; Inui N; Kawakami J; Watanabe H; Namiki N Biol Pharm Bull; 2019; 42(9):1590-1595. PubMed ID: 31474719 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. Lee TC; Charles BG; Harte GJ; Gray PH; Steer PA; Flenady VJ Anesthesiology; 1999 Feb; 90(2):451-7. PubMed ID: 9952152 [TBL] [Abstract][Full Text] [Related]
11. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population. Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145 [TBL] [Abstract][Full Text] [Related]
12. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371 [TBL] [Abstract][Full Text] [Related]
13. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN; Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518 [TBL] [Abstract][Full Text] [Related]
14. Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. Völler S; Flint RB; Beggah F; Reiss I; Andriessen P; Zimmermann LJI; van den Anker JN; Liem KD; Koch BCP; de Wildt S; Knibbe CAJ; Simons SHP J Clin Pharmacol; 2019 Oct; 59(10):1300-1308. PubMed ID: 31093992 [TBL] [Abstract][Full Text] [Related]
15. Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. Pecking M; Montestruc F; Marquet P; Wodey E; Homery MC; Dostert P Br J Clin Pharmacol; 2002 Oct; 54(4):357-62. PubMed ID: 12392582 [TBL] [Abstract][Full Text] [Related]
16. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Knibbe CA; Krekels EH; van den Anker JN; DeJongh J; Santen GW; van Dijk M; Simons SH; van Lingen RA; Jacqz-Aigrain EM; Danhof M; Tibboel D Clin Pharmacokinet; 2009; 48(6):371-85. PubMed ID: 19650676 [TBL] [Abstract][Full Text] [Related]
17. Dose-linearity of the pharmacokinetics of an intravenous [ van Groen BD; Vaes WH; Park BK; Krekels EHJ; van Duijn E; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Knibbe CAJ; Tibboel D; de Wildt SN; Turner MA Br J Clin Pharmacol; 2019 Oct; 85(10):2332-2340. PubMed ID: 31269280 [TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Ahsman MJ; Hanekamp M; Wildschut ED; Tibboel D; Mathot RA Clin Pharmacokinet; 2010 Jun; 49(6):407-19. PubMed ID: 20481651 [TBL] [Abstract][Full Text] [Related]
19. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of intravenous and oral midazolam in preterm infants. de Wildt SN; Kearns GL; Sie SD; Hop WC; van den Anker JN Clin Drug Investig; 2003; 23(1):27-38. PubMed ID: 23319091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]